Thermo Scientific Tandem Mass Tag Research Award
Applications for the 4th Annual Tandem Mass Tag Research Award for doctoral and post-doctoral students being accepted from September 17, 2017 through February 28, 2018

Describe how you will use Thermo Scientific tandem mass tag (including amine-, sulfhydryl-, or carbonyl-reactive) labeling reagents and Thermo Scientific mass spectrometry (MS) reagents in your research, and you could receive one of three awards that provide up to $10,000 worth of these reagents, free for use in your doctoral or post-doctoral research.

The research awards include eligible Thermo Scientific MS reagents, with up to 50% of each grant available for tandem mass tag labeling reagents. The top three recipients will be selected by a panel of judges from Thermo Fisher Scientific and Proteome Sciences, based on the recipient’s innovative and impactful intended use of the TMT reagents. Award recipients will be recognized during a Thermo Scientific sponsored event at ASMS in San Diego, California on June 3–7, 2018.

For more information, and to see a list of eligible products, download our promotional flier.

Past award recipients

Roman Fischer, University of Oxford, Oxford, UK

Dr. Fischer leads the Discovery Proteomics Facility and is a principal investigator at the University of Oxford, UK. His lab focusses on proteomic strategies to access the deep proteome from minimal sample materials, such as cells harvested by laser-capture-microdissection. Employing a series of recently published techniques (GASP, CHOPIN) they aim at not only comprehensive proteome-, but also proteome sequence coverage to detect protein isoforms and PTMs in the context of tumor biology and drug target.

Kathryn Lilley, University of Cambridge, Cambridge, UK

Dr. Lilley is a research group leader in the Department of Biochemistry, University of Cambridge, UK. She is also the Director, Cambridge Centre for Proteomics and Head of Cambridge Systems Biology Centre. She has been at the forefront of technology development enabling mapping of the spatial proteome. Her current work investigates the implications of where transcripts are translated upon the spatial proteome and protein structure and how this process is controlled. 

Domitille Schvartz, University of Geneva, Geneva, Switzerland

Dr. Schvartz is working in the Translational Biomarker Group headed by Pr. Jean-Charles Sanchez at the University of Geneva. The group has conducted studies over the years for the discovery of diagnostic and prognostic biomarkers of brain injuries using proteomic approaches on body fluids. She has applied many “omics” approaches to her own research projects, mainly on type 2 diabetes. She is also the chair of a worldwide initiative of the Human Proteome Organization, gathering researchers in the field of diabetes and proteomics. She is now involved in a project aimed at discovering early biomarkers of drug-induced liver injury (DILI) by quantitative “omics”.

 Poster: Plasma-derived icroparticle biomarkers of paracetamol-induced hepatotoxicity

Learn more about past award recipients

Gold level recipient: $10,000

Roman Fischer, University of Oxford, Oxford, UK

Dr. Fischer leads the Discovery Proteomics Facility and is a principal investigator at the University of Oxford, UK. His lab focusses on proteomic strategies to access the deep proteome from minimal sample materials, such as cells harvested by laser-capture-microdissection. Employing a series of recently published techniques (GASP, CHOPIN) they aim at not only comprehensive proteome-, but also proteome sequence coverage to detect protein isoforms and PTMs in the context of tumor biology and drug target.


Silver level recipient: $7500

Kathryn Lilley, University of Cambridge, Cambridge, UK

Dr. Lilley is a research group leader in the Department of Biochemistry, University of Cambridge, UK. She is also the Director, Cambridge Centre for Proteomics and Head of Cambridge Systems Biology Centre. She has been at the forefront of technology development enabling mapping of the spatial proteome. Her current work investigates the implications of where transcripts are translated upon the spatial proteome and protein structure and how this process is controlled. 


Bronze level recipient: $5000

Kilian Huber, University of Oxford, Oxford, UK

Dr. Huber is a Principal Investigator at the Structural Genomics Consortium and Target Discovery Institute at the Nuffield Department of Clinical Medicine. His research laboratory uses a combination of chemistry and biology to develop small molecule tool compounds to explore protein function and probe cellular signaling networks related to human disease research. A second key area of interest is the development of chemical biology approaches to investigate the mechanism of action of drugs and other pharmacologically active compounds to identify future novel therapeutic targets.


Bronze level recipient: $5000

Ashok Reddy, Oregon Health & Sciences University, Portland, OR

Dr. Ashok Reddy is the associate director of the Oregon Health & Sciences University Proteomics Shared Resource, and is responsible for managing proteomics projects across the entire university. He has 15 years of experience conducting cancer research and proteomics/biomarker discovery studies in human body fluids. He has managed these proteomics projects from conception to discovery as demonstrated by the discovery of candidate biomarkers of infection for pre-term birth, preeclampsia, and neonatal sepsis. His research interests are in discovery and validation of disease biomarkers in body fluids, tissues and exosomes.

Gold level recipient: $10,000

Noah Dephoure, Weill Cornell Medical College,
New York, NY

Dr. Dephoure is an Assistant Professor at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College. His lab develops and refines proteomic tools and uses them to study signaling events that underlie basic cellular biology and human disease research. A long-term goal of the lab is to understand the complex roles of posttranslational protein modifications (PTMs) in cellular growth and proliferation. By combining multiplexed quantitative and temporal analysis of PTMs with novel methods for studying changes in protein interactions and subcellular localization, they are decoding the mechanisms by which these simple chemical changes impact oncogenesis and tumor progression.


Silver level recipient: $7,500

Domitille Schvartz, University of Geneva, Geneva, Switzerland

Dr. Schvartz is working in the Translational Biomarker Group headed by Pr. Jean-Charles Sanchez at the University of Geneva. The group has conducted studies over the years for the discovery of diagnostic and prognostic biomarkers of brain injuries using proteomic approaches on body fluids. She has applied many “omics” approaches to her own research projects, mainly on type 2 diabetes. She is also the chair of a worldwide initiative of the Human Proteome Organization, gathering researchers in the field of diabetes and proteomics. She is now involved in a project aimed at discovering early biomarkers of drug-induced liver injury (DILI) by quantitative “omics”.

 Poster: Plasma-derived icroparticle biomarkers of paracetamol-induced hepatotoxicity


Bronze level recipient: $5,000

Sina Ghaemmaghami, University of Rochester, Rochester, NY

Sina Ghaemmaghami is an assistant professor of biology at the University of Rochester. His research focuses on understanding the mechanisms of cellular protein folding and degradation with a special focus on neurodegenerative disorders. He has authored more than 30 publications in journals such as Science, Nature, and PNAS. His laboratory has developed a number of commonly used proteomic methodologies for global analyses of cellular protein homeostasis.  


Matthias Trost, University of Dundee, Scotland

His lab focuses on using proteomics to understand cell signaling via phosphorylation and ubiquitylation in vesicle trafficking in macrophages. They use their expertise in this area to characterize molecular mechanisms in Parkinson’s disease. Recently, they started developing mass spectrometry tools for identification of potential drug targets and drug discovery.

Jun Qu, SUNY, Buffalo, NY

His lab develops and applies LC/MS-based strategies for research in the fields of proteomics and pharmaceutical analysis, involving high-resolution and large-scale expression profiling of pathological proteomes (e.g., for cardiovascular diseases, colon cancer, and infectious diseases) for the discovery of disease/therapeutic biomarkers; identification, localization, and quantification of post-translational modifications in complex proteomes; and targeted quantification of regulatory marker proteins for research study.

Jon Reed, Roskamp Institute, Sarasota, FL

His MS lab uses integrative -omic approaches (proteomics, lipidomics, metabolomics) as well as DMPK analyses to elucidate the underlying mechanisms of several neurodegenerative diseases, and to facilitate the development of therapeutic approaches.  The use of stable isotope tagging such as the TMT reagents is integral to day-to-day operations, owing to the increases in throughput and assay standardization observed relative to other techniques.